Filings & corporate actions
77 results filed
CSVNext results · Q2 FY27
Expected 24 Oct 2026 – 14 Nov 2026
Estimate: filed 24–45 days after quarter end, last 5 times
Dividend
₹5.00 per share · last 31 Jul 2026
2026
- 31 JulresultsResults · Q1 FY27 · consolidated and standalone+0.3%NSE
- 31 JuldividendDividend · ₹5.00 per share-4.5%
- 20 JulshareholdingShareholding · 30 Jun 2026-1.4%NSE
- 18 MayresultsResults · Q4 FY26 · consolidated and standalone+0.2%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026-0.4%NSE
- 30 JanresultsResults · Q3 FY26 · consolidated and standalone-1.6%NSE
- 19 JanshareholdingShareholding · 31 Dec 2025-3.4%NSE
Reaction to results · all yearsrose on day 0 in 32 of 74 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 31 Jul 2026 | +0.3% | -2.5% | 0.0% | 2.1× |
| Q4 FY26 | 18 May 2026 | +0.2% | +1.5% | -3.9% | 3.5× |
| Q3 FY26 | 30 Jan 2026 | -1.6% | -1.5% | -2.9% | 0.9× |
| Q2 FY26 | 31 Oct 2025 | +5.4% | -1.0% | -3.8% | 6.9× |
| Q1 FY26 | 29 Jul 2025 | +3.5% | -10.9% | -8.4% | 4.3× |
| Q4 FY25 | 22 May 2025 | +0.2% | +11.1% | +13.2% | 3.0× |
| Q3 FY25 | 30 Jan 2025 | +4.1% | +10.7% | -5.9% | 1.6× |
| Q2 FY25 | 24 Oct 2024 | -1.7% | +1.8% | -7.1% | 2.1× |
| Q1 FY25 | 29 Jul 2024 | +3.4% | +3.4% | +26.8% | 4.3× |
| Q4 FY24 | 22 May 2024 | -3.0% | -7.0% | +5.1% | 1.2× |
| Q3 FY24 | 30 Jan 2024 | -0.1% | +1.3% | +11.9% | 0.7× |
| Q2 FY24 | 31 Oct 2023 | -2.5% | -0.3% | -0.6% | 0.7× |
| Q1 FY24 | 2 Aug 2023 | -7.1% | -8.9% | -7.6% | 3.8× |
| Q4 FY23 | 25 May 2023 | +4.0% | -1.1% | +13.6% | 3.1× |
| Q3 FY23 | 25 Jan 2023 | +1.2% | -5.5% | -6.3% | 2.5× |
| Q2 FY23 | 14 Nov 2022 | +0.1% | -5.6% | +8.4% | 2.0× |
| Q1 FY23 | 29 Jul 2022 | +1.3% | +2.9% | +0.6% | 0.7× |
| Q4 FY22 | 25 May 2022 | +1.0% | +8.5% | -2.0% | 3.6× |
| Q3 FY22 | 10 Feb 2022 | -1.0% | -6.8% | -17.3% | 1.4× |
| Q2 FY22 | 10 Nov 2021 | -3.3% | -1.2% | -8.6% | 2.8× |
| Q1 FY22 | 6 Aug 2021 | -7.0% | -13.5% | -18.1% | 3.9× |
| Q4 FY21 | 27 May 2021 | -1.6% | -2.5% | -6.0% | 1.1× |
| Q3 FY21 | 4 Feb 2021 | -0.9% | -3.3% | -3.2% | 3.1× |
| Q2 FY21 | 29 Oct 2020 | +2.4% | -1.9% | +18.2% | 1.6× |
| Q1 FY21 | 5 Aug 2020 | -1.6% | +5.1% | +13.8% | 3.1× |
| Q4 FY20 | 21 May 2020 | +0.2% | -5.4% | -4.1% | 2.5× |
| Q3 FY20 | 30 Jan 2020 | +4.9% | +10.6% | +5.2% | 6.9× |
| Q2 FY20 | 25 Oct 2019 | +2.3% | +6.6% | +5.0% | 1.1× |
| Q1 FY20 | 29 Jul 2019 | +5.2% | +16.6% | +5.2% | 10.2× |
| Q4 FY19 | 10 May 2019 | -10.1% | -12.8% | -11.1% | 4.0× |
| Q3 FY19 | 31 Jan 2019 | -3.4% | -9.0% | -6.0% | 1.0× |
| Q2 FY19 | 21 Nov 2018 | -2.0% | +5.9% | +0.4% | 0.4× |
| Q1 FY19 | 23 Aug 2018 | +0.7% | +3.8% | -2.9% | 0.8× |
| Q4 FY18 | 21 Jun 2018 | +0.5% | +0.4% | -11.9% | 1.1× |
| Q3 FY18 | 22 Feb 2018 | +1.8% | +3.4% | +0.1% | 0.7× |
| Q2 FY18 | 1 Nov 2017 | -0.3% | -6.4% | -1.1% | 0.8× |
| Q1 FY18 | 21 Aug 2017 | +1.2% | +1.0% | +12.7% | 0.8× |
| Q4 FY17 | 18 Jun 2017 | -0.9% | -1.7% | +9.3% | 0.2× |
| Q3 FY17 | 6 Feb 2017 | +1.4% | -1.3% | -3.6% | 0.8× |
| Q2 FY17 | 7 Nov 2016 | -0.9% | -6.1% | -1.3% | 0.8× |
| Q1 FY17 | 27 Sept 2016 | -0.4% | -2.9% | -10.4% | 0.5× |
| Q4 FY16 | 17 May 2016 | -2.4% | -13.6% | -5.9% | 1.4× |
| Q3 FY16 | 13 Feb 2016 | -0.2% | -1.6% | +8.1% | 0.9× |
| Q2 FY16 | 29 Oct 2015 | -0.4% | -4.5% | +4.8% | 1.0× |
| Q1 FY16 | 31 Jul 2015 | -2.4% | +2.6% | -3.8% | 1.2× |
| Q4 FY15 | 26 May 2015 | +4.2% | +2.7% | +0.9% | 1.5× |
| Q3 FY15 | 4 Feb 2015 | -1.2% | -3.8% | +13.7% | 0.5× |
| Q2 FY15 | 24 Nov 2014 | +1.0% | +19.7% | +21.9% | 0.8× |
| Q1 FY15 | 1 Aug 2014 | -1.0% | +0.8% | +0.2% | 0.5× |
| Q3 FY14 | 12 Feb 2014 | -1.6% | -3.6% | -2.5% | 0.4× |
| Q2 FY14 | 22 Nov 2013 | -1.0% | -1.9% | -62.1% | 0.7× |
| Q1 FY14 | 26 Jul 2013 | +0.7% | -2.2% | +17.0% | 0.8× |
| Q4 FY13 | 8 May 2013 | -1.6% | -0.2% | -1.9% | 0.7× |
| Q3 FY13 | 28 Feb 2013 | -6.9% | -7.8% | -11.9% | 5.6× |
| Q2 FY13 | 29 Oct 2012 | -0.4% | -1.4% | +24.6% | 0.5× |
| Q1 FY13 | 27 Jul 2012 | +2.0% | +7.3% | +18.0% | 0.5× |
| Q4 FY12 | 9 May 2012 | 0.0% | -1.6% | +3.0% | 0.6× |
| Q3 FY12 | 27 Feb 2012 | -2.1% | +2.7% | +4.9% | 0.7× |
| Q2 FY12 | 24 Oct 2011 | -0.8% | +6.5% | +4.8% | 1.2× |
| Q1 FY12 | 27 Jul 2011 | -0.8% | -2.8% | -25.5% | 1.4× |
| Q4 FY11 | 25 Apr 2011 | 0.0% | -1.3% | -5.3% | 2.2× |
| Q2 FY11 | 27 Oct 2010 | -2.4% | -0.8% | -9.0% | 2.6× |
| Q1 FY11 | 27 Jul 2010 | -3.7% | +5.9% | -0.1% | 1.3× |
| Q4 FY10 | 22 Apr 2010 | +0.9% | -6.7% | -3.8% | 2.5× |
| Q2 FY10 | 30 Oct 2009 | -2.7% | +6.1% | +35.6% | 1.4× |
| Q1 FY10 | 30 Jul 2009 | +9.8% | +1.3% | +2.9% | 3.5× |
| Q4 FY09 | 24 Apr 2009 | -8.7% | -1.7% | +19.4% | 0.5× |
| Q2 FY09 | 31 Oct 2008 | +6.0% | -12.9% | -19.2% | 1.1× |
| Q1 FY09 | 22 Jul 2008 | +16.5% | +22.1% | +26.2% | 9.1× |
| Q4 FY08 | 28 Apr 2008 | +9.8% | +12.6% | -8.1% | 2.1× |
| Q3 FY08 | 7 Mar 2008 | -3.4% | -4.3% | +36.7% | 0.5× |
| Q2 FY08 | 30 Oct 2007 | +0.8% | -1.1% | +6.1% | 1.0× |
| Q1 FY08 | 27 Jul 2007 | -0.7% | -7.7% | -10.4% | 0.9× |
| Q4 FY07 | 26 Apr 2007 | -3.6% | -6.7% | -5.5% | 5.3× |
| Average | -0.0% | -0.3% | +0.9% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+13.0%
Profit YoY+56.7%
Interest cost YoY-26.1%
Revenue QoQ-4.4%
Profit QoQ+28.0%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +9.0% | +10.8% | — | +9.2% | +9.9% | +7.3% |
| Profit | — | — | — | — | +30.3% | +9.5% |
Key data
CSVOpen1,081.20
Day range1,074.00 – 1,096.20
52-week range768.65 – 1,260.90
From 52w high-13.7%
RSI (14)42.7
ATR (14)43.12
Volume1.38L
Avg volume (20D)3.89L
Rel volume0.36×
Volatility (1Y)38.3%
Turnover₹15.1Cr
SMA 50 / 2001,074.46 / 1,006.83
Delivery percentage
Latest · 6 Oct 202653.0%
20-day avg45.6%
1-year avg44.0%
Percentile (own history)86th
Range7.8–100.0%
Sessions1,731
Over the last 20 sessions STAR settled 45.6% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 44.0%. The latest session ranks higher than 86% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.18% | -5.45% | +3.33% | -3.50% | +12.10% | +33.50% |
Valuation
CSVMarket cap₹10,035 Cr
P/E (TTM)15.8
EPS (TTM)68.83
Shares outstanding9.22Cr
Listed2 Feb 2000
Ownership
CSVPromoter27.91%
Promoter Δ QoQ0.00 pp
Public72.09%
FII28.39%
DII15.41%
Pledged38.10%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 1,220.8 | 1,194.6 | 1,323.5 | 1,265.4 |
| YoY chg | +1.6% | +3.6% | +11.2% | +13.0% |
| Net profit (₹ Cr) | 131.5 | 208.1 | 129.3 | 165.5 |
| YoY chg | +40.4% | +131.1% | +51.0% | +56.7% |
| Net margin | 10.8% | 17.4% | 9.8% | 13.1% |
| EPS | 13.84 | 21.92 | 13.77 | 17.02 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 27.91% · public 72.09%2021-092026-06
- Promoter
- Public and others
- Promoter
- 27.91%
- Public
- 72.09%
- Promoter change
- 0.00 pp
- Filed
- 20 Jul 2026
- FII
- 28.39%
- DII
- 15.41%
- Promoter pledged
- 38.10%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 999.4 | 1,037.7 | 1,084.0 | 1,087.5 | 1,201.1 | 1,153.7 | 1,190.4 | 1,119.7 | 1,220.8 | 1,194.6 | 1,323.5 | 1,265.4 | |
| Other income | 35.8 | 8.8 | (13.5) | 12.7 | 28.4 | 5.6 | 12.0 | 8.6 | 27.1 | 106.9 | 8.1 | 4.9 | |
| Total income | 1,035.3 | 1,046.4 | 1,070.5 | 1,100.2 | 1,229.5 | 1,159.3 | 1,202.4 | 1,128.3 | 1,248.0 | 1,301.5 | 1,331.6 | 1,270.3 | |
| Total expenses | 985.0 | 974.4 | 984.2 | 999.5 | 1,098.0 | 1,044.0 | 1,071.7 | 998.0 | 1,085.0 | 1,052.7 | 1,178.6 | 1,132.6 | |
| └ Finance costs | 78.6 | 79.3 | 80.2 | 80.4 | 82.1 | 52.2 | 50.3 | 47.5 | 46.1 | 43.4 | 41.6 | 40.6 | |
| └ Depreciation | 60.1 | 51.2 | 49.8 | 48.6 | 50.5 | 48.4 | 48.9 | 48.9 | 49.6 | 50.6 | 53.2 | 56.4 | |
| Profit before tax | (114.6) | 62.0 | 78.2 | 97.0 | 127.7 | 112.9 | 103.3 | 121.9 | 154.2 | 245.5 | 146.6 | 200.9 | |
| Tax expense | (7.4) | 10.1 | 19.3 | 16.9 | 21.2 | 23.8 | 20.8 | 16.5 | 21.6 | 37.4 | 18.8 | 34.1 | |
| Net profit | (149.5) | 54.1 | 10.4 | 68.3 | 93.7 | 90.0 | 85.6 | 105.6 | 131.5 | 208.1 | 129.3 | 165.5 | |
| EPS | -14.54 | 5.43 | 1.98 | 7.64 | 10.14 | 9.56 | 8.92 | 10.81 | 13.84 | 21.93 | 13.77 | 17.02 | |
| Net margin | -14.95% | 5.21% | 0.96% | 6.28% | 7.80% | 7.80% | 7.19% | 9.43% | 10.77% | 17.42% | 9.77% | 13.08% | |
| PBT margin | -11.47% | 5.97% | 7.21% | 8.92% | 10.63% | 9.79% | 8.67% | 10.89% | 12.63% | 20.55% | 11.08% | 15.88% | |
| Tax rate | — | 16.30% | 24.62% | 17.39% | 16.61% | 21.09% | 20.11% | 13.49% | 14.01% | 15.21% | 12.80% | 16.98% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 31 Jul 2026.
STAR at a glance
- STAR closed at ₹1,088.7 on 6 Oct 2026, +0.18% on the day, +33.5% over one year, 13.7% below its 52-week high of ₹1,260.9.
- Delivery was 53.0% of traded quantity on 6 Oct 2026, the 86th percentile of its own 1,731 sessions with a reading (20-session average 45.6%, 1-year average 44.0%).
- Market capitalisation is ₹10,035 crore at a trailing P/E of 15.8 (trailing EPS ₹68.83).
- Q1 FY27 results (consolidated, filed 31 Jul 2026): revenue ₹1,265 crore (+13.0% year on year), net profit ₹165 crore (+56.7%); the price moved +0.3% on the first session after.
- Promoters held 27.91% at 30 Jun 2026, unchanged on the previous filing, with 38.10% of promoter shares pledged.
- Q2 FY27 results are expected between 24 Oct 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE939A01011
SeriesEQ
Listed2 Feb 2000
History from19 Aug 2003
Sessions5,742
Turnover rank#507
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE